Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jan 26, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This looked at the safety and effectiveness of copanlisib (Aliqopa) for B-cell lymphoma that returned after previous treatment. This study found that long-term copanlisib treatment was safe and effective.

Some background

Indolent (painless) B-cell lymphoma is a slow-growing blood cancer. B-cell lymphoma that comes back or stops responding to treatment (refractory) can be difficult to treat. Targeted therapy is one treatment option for these patients.

PI3K inhibitors are a targeted therapy. These agents block cancer cell growth. Although they are effective, PI3K inhibitors are associated with serious side effects, such as infections. Copanlisib is a PI3K inhibitor with fewer side effects. Whether long-term treatment with copanlisib is safe remains unclear.

Methods & findings

This study followed 142 patients with B-cell lymphoma who relapsed after at least two previous treatments. Most patients (104) had follicular lymphoma (FL). In this study, patients received at least 4 cycles of copanlisib. Patients were followed for an average of 2 years.

Overall, 60.6% of patients responded to treatment. 16.9% of patients had no signs of cancer after treatment. 43.7% of patients had tumor shrinkage.

Overall, patients survived for an average of 42.6 months. Patients survived for an average of 12.5 months before the cancer began to get worse.

98.6% of patients had at least one side effect. The most common ones were low blood glucose levels (50.0%), diarrhea (35.2%), and low white blood cell levels (28.9%). Fever (28.9%) and fatigue (26.1%) were also reported.

55.6% of patients had serious side effects. These included pneumonia (11.3%), fever (6.3%), and low blood glucose levels (4.9%). Among patients who were treated for more than 1 year, no new side effects or worsening side effects were reported.

The bottom line

The study concluded that copanlisib is an effective long-term treatment for patients with relapsed B-cell lymphoma, with manageable side effects.

The fine print

This study was supported by Bayer AG, the manufacturer of copanlisib.

Published By :

American Journal of Hematology

Date :

Dec 23, 2019

Original Title :

Long-term safety and efficacy of the PI3K- inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.

click here to get personalized updates